ERBB2 and breast carcinoma: Our observation that EDI3 expression and enzymatic activity is highest in breast cancer cells of the ER-HER2+ subtype, as well as in human ER-HER2+ breast cancers [6], motivated us to focus on this specific molecular breast cancer subtype.